Overview

PTH and Vibration in OSteoporosis Study

Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
0
Participant gender:
Female
Summary
Objective: This is a randomized controlled trial (RCT) in osteoporosis patients randomized to standard parathyroid hormone (PTH) treatment alone or to standard PTH treatment and Whole-body vibration (WBV). PTH is an effective but expensive anabolic treatment for osteoporosis. WBV stimulates muscles and bones. A combined treatment might have synergistic or additive beneficial effects on bone, reducing fracture risk making treatment more effective and cost-effective. A beneficial effect on muscles and thereby falls risk of WBV may improve fracture risk even further. If the results of this pilot study are promising then a strong case can be made for a large multi-centre RCT using strong endpoints including fractures and falls.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Odense University Hospital
Collaborators:
Copenhagen University Hospital, Denmark
Hospital of South West Denmark
Odense Patient Data Explorative Network
OPEN - Odense Patient data Explorative Network
Region of Southern Denmark
Sygehus Lillebaelt
University of Southern Denmark
Treatments:
Teriparatide
Criteria
Inclusion Criteria:

- Women starting PTH treatment for osteoporosis according to Danish Osteoporosis
guidelines

Exclusion Criteria:

- Women currently taking oral glucocorticoids

- Women unable to give informed consent

- Women unable to stand for 2 minutes at a time on the vibration platform

- Women who have contraindications to WBV (e.g. joint prosthesis, pacemakers)